223 related articles for article (PubMed ID: 26877821)
1. Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer.
Clermont PL; Crea F; Chiang YT; Lin D; Zhang A; Wang JZ; Parolia A; Wu R; Xue H; Wang Y; Ding J; Thu KL; Lam WL; Shah SP; Collins CC; Wang Y; Helgason CD
Clin Epigenetics; 2016; 8():16. PubMed ID: 26877821
[TBL] [Abstract][Full Text] [Related]
2. Polycomb-mediated silencing in neuroendocrine prostate cancer.
Clermont PL; Lin D; Crea F; Wu R; Xue H; Wang Y; Thu KL; Lam WL; Collins CC; Wang Y; Helgason CD
Clin Epigenetics; 2015; 7(1):40. PubMed ID: 25859291
[TBL] [Abstract][Full Text] [Related]
3. A Potent, Selective CBX2 Chromodomain Ligand and Its Cellular Activity During Prostate Cancer Neuroendocrine Differentiation.
Wang S; Alpsoy A; Sood S; Ordonez-Rubiano SC; Dhiman A; Sun Y; Jiao G; Krusemark CJ; Dykhuizen EC
Chembiochem; 2021 Jul; 22(13):2335-2344. PubMed ID: 33950564
[TBL] [Abstract][Full Text] [Related]
4. Beyond EZH2: is the polycomb protein CBX2 an emerging target for anti-cancer therapy?
Jangal M; Lebeau B; Witcher M
Expert Opin Ther Targets; 2019 Jul; 23(7):565-578. PubMed ID: 31177918
[No Abstract] [Full Text] [Related]
5. LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer.
Wang D; Ding L; Wang L; Zhao Y; Sun Z; Karnes RJ; Zhang J; Huang H
Oncotarget; 2015 Dec; 6(38):41045-55. PubMed ID: 26516927
[TBL] [Abstract][Full Text] [Related]
6. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome.
Yu J; Yu J; Rhodes DR; Tomlins SA; Cao X; Chen G; Mehra R; Wang X; Ghosh D; Shah RB; Varambally S; Pienta KJ; Chinnaiyan AM
Cancer Res; 2007 Nov; 67(22):10657-63. PubMed ID: 18006806
[TBL] [Abstract][Full Text] [Related]
7. ERG protein expression and gene rearrangements are present at lower rates in metastatic and locally advanced castration-resistant prostate cancer compared to localized disease.
Teng LH; Wang C; Bégin LR; Dolph M; Yilmaz A; Trpkov K; Donnelly B; Bismar TA
Urology; 2013 Aug; 82(2):394-9. PubMed ID: 23746715
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic modulations and lineage plasticity in advanced prostate cancer.
Ge R; Wang Z; Montironi R; Jiang Z; Cheng M; Santoni M; Huang K; Massari F; Lu X; Cimadamore A; Lopez-Beltran A; Cheng L
Ann Oncol; 2020 Apr; 31(4):470-479. PubMed ID: 32139297
[TBL] [Abstract][Full Text] [Related]
9. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C
Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598
[TBL] [Abstract][Full Text] [Related]
10. Multiomics integrative analysis reveals antagonistic roles of CBX2 and CBX7 in metabolic reprogramming of breast cancer.
Iqbal MA; Siddiqui S; Ur Rehman A; Siddiqui FA; Singh P; Kumar B; Saluja D
Mol Oncol; 2021 May; 15(5):1450-1465. PubMed ID: 33400401
[TBL] [Abstract][Full Text] [Related]
11. Expression screening of cancer/testis genes in prostate cancer identifies NR6A1 as a novel marker of disease progression and aggressiveness.
Mathieu R; Evrard B; Fromont G; Rioux-Leclercq N; Godet J; Cathelineau X; Guillé F; Primig M; Chalmel F
Prostate; 2013 Jul; 73(10):1103-14. PubMed ID: 23532770
[TBL] [Abstract][Full Text] [Related]
12. The HDAC inhibitor SAHA regulates CBX2 stability via a SUMO-triggered ubiquitin-mediated pathway in leukemia.
Di Costanzo A; Del Gaudio N; Conte L; Dell'Aversana C; Vermeulen M; de Thé H; Migliaccio A; Nebbioso A; Altucci L
Oncogene; 2018 May; 37(19):2559-2572. PubMed ID: 29467492
[TBL] [Abstract][Full Text] [Related]
13. MiR-361-5p acts as a tumor suppressor in prostate cancer by targeting signal transducer and activator of transcription-6(STAT6).
Liu D; Tao T; Xu B; Chen S; Liu C; Zhang L; Lu K; Huang Y; Jiang L; Zhang X; Huang X; Zhang L; Han C; Chen M
Biochem Biophys Res Commun; 2014 Feb; 445(1):151-6. PubMed ID: 24491557
[TBL] [Abstract][Full Text] [Related]
14. Combination simvastatin and metformin induces G1-phase cell cycle arrest and Ripk1- and Ripk3-dependent necrosis in C4-2B osseous metastatic castration-resistant prostate cancer cells.
Babcook MA; Sramkoski RM; Fujioka H; Daneshgari F; Almasan A; Shukla S; Nanavaty RR; Gupta S
Cell Death Dis; 2014 Nov; 5(11):e1536. PubMed ID: 25412314
[TBL] [Abstract][Full Text] [Related]
15. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
[TBL] [Abstract][Full Text] [Related]
16. Identification of hepatocellular carcinoma subtypes based on PcG-related genes and biological relevance with cancer cells.
Fu Y; Yang K; Wu K; Wang H; Li Q; Zhang F; Yang K; Yao Q; Ma X; Deng Y; Zhang J; Liu C; Qu K
Clin Epigenetics; 2022 Dec; 14(1):184. PubMed ID: 36566204
[TBL] [Abstract][Full Text] [Related]
17. TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling.
Ibuki N; Ghaffari M; Pandey M; Iu I; Fazli L; Kashiwagi M; Tojo H; Nakanishi O; Gleave ME; Cox ME
Int J Cancer; 2013 Oct; 133(8):1955-66. PubMed ID: 23564295
[TBL] [Abstract][Full Text] [Related]
18. Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model.
Knuuttila M; Yatkin E; Kallio J; Savolainen S; Laajala TD; Aittokallio T; Oksala R; Häkkinen M; Keski-Rahkonen P; Auriola S; Poutanen M; Mäkelä S
Am J Pathol; 2014 Aug; 184(8):2163-73. PubMed ID: 24949550
[TBL] [Abstract][Full Text] [Related]
19. Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.
Shiota M; Takeuchi A; Song Y; Yokomizo A; Kashiwagi E; Uchiumi T; Kuroiwa K; Tatsugami K; Fujimoto N; Oda Y; Naito S
Endocr Relat Cancer; 2011 Aug; 18(4):505-17. PubMed ID: 21652770
[TBL] [Abstract][Full Text] [Related]
20. [Molecular targeting drug of kinase inhibitors for castration resistant prostate cancer].
Kosaka T; Oya M
Nihon Rinsho; 2014 Dec; 72(12):2186-92. PubMed ID: 25518356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]